Sign Up Today and Learn More About Tempus Stock
Invest in or calculate the value of your shares in Tempus or other pre-IPO companies through EquityZen's platform.
About Tempus Stock
Founded
2015
Headquarters
Chicago, IL, US
Total Funding
520M
Industries
Software, Data and Analytics, Science and Engineering
Tempus is a technology-enabled precision medicine solutions company that has built an operating system to battle cancer. It is on a mission to redefine how genomic data is used in a clinical setting. Their goal is for each patient to benefit from the treatment of others who came before by enabling physicians to deliver personalized cancer care for patients through interactive analytical and machine learning platform. Eric Lefkofsky founded it in 2015 and is headquartered in Chicago, Illinois.
Tempus Press Mentions
Stay in the know about the latest news on Tempus
Tempus Announces Collaboration with IFLI Aimed at Supporting Development of Targeted Therapies for Follicular Lymphoma
businesswire • Feb 13, 2025
Tempus Announces Collaboration with IFLI Aimed at Supporting Development of Targeted Therapies for Follicular Lymphoma
marketscreener • Feb 13, 2025
Other news to note for Feb. 12, 2025
bioworld • Feb 13, 2025
Precision Medicine Solution Market to Reach USD 453.4 Billion by 2032 | Exploring Growth of Precision Medicine Solutions
einpresswire • Jan 22, 2025
Tempus Announces a Collaboration With
businesswire • Jan 08, 2025
Investors in Tempus
Discover investors in Tempus stock and explore their portfolio companies
Tempus Management
Leadership team at Tempus
Chief Executive Officer
Eric Lefkofsky
Chief Financial Officer
Jim Rogers
Join now and verify your accreditation status to gain access to:
- Tempus Current Valuation
- Tempus Stock Price
- Tempus Management
- Available deals in Tempus and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Tempus Cap Table and Funding History by Share Class and Liquidity Preferences
- Tempus Revenue and Financials
- Tempus Highlights
- Tempus Business Model
- Tempus Risk Factors
- Tempus Research Report from SACRA Research
Trading Tempus Stock
How to invest in Tempus stock?
Accredited investors can buy pre-IPO stock in companies like Tempus through EquityZen funds. These investments are made available by existing Tempus shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Tempus stock?
Shareholders can sell their Tempus stock through EquityZen's private company marketplace. EquityZen's network includes over 350K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 44K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
